▶ SS-31 · SUBTOPIC · MECHANISM
SS-31 Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Mitochondrial-targeted tetrapeptide (Elamipretide / Bendavia / MTP-131). Selectively binds cardiolipin on the inner mitochondrial membrane to stabilize cristae structure and preserve electron-transport-chain coupling under stress.
PHARMACOKINETIC HALF-LIFE
Reported half-life for SS-31: ~3 hours plasma. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
PRIMARY SEQUENCE
SS-31 is a defined sequence: D-Arg-(2',6'-dimethylTyr)-Lys-Phe-NH2. Synthesis proceeds via solid-phase peptide synthesis with HPLC-verified identity confirmation.
MECHANISM CATEGORIES
SS-31 is tagged in 2 mechanism categories on GIGARESEARCH. Each category aggregates the broader pharmacology of related compounds.
Mitochondrial function encompasses oxidative phosphorylation, biogenesis (driven by PGC-1α), and quality-control processes (mitophagy). The mitochondrial-derived peptide MOTS-c regulates AMPK signaling and metabolic homeostasis. NAD+ supports the electron-transport chain and mitochondrial sirtuins (SIRT3, SIRT4, SIRT5).
The longevity category includes compounds acting on canonical aging-biology pathways: sirtuins (NAD+-dependent deacylases), mitochondrial function and biogenesis, cellular senescence, autophagy, and the AMPK/mTOR axis. NAD+ and its precursors are the most-studied longevity compounds; MOTS-c (mitochondrial-derived peptide) is an emerging category.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Well-characterized cardiolipin interaction on the inner mitochondrial membrane. Szeto lab multi-paper biochemistry.
Multiple rodent and large-animal models report reduced infarct size and preserved ATP under ischemic stress.
Stealth BioTherapeutics Phase 2/3 program in Barth syndrome and primary mitochondrial myopathy. Mixed primary-endpoint outcomes; signal in functional sub-measures.
Stealth ReNEW / ReGAIN trials in dry AMD reported mixed results. FDA approval pending as of 2026.
MECHANISM Q+A
▶ SS-31 vs MOTS-c · what's different?
Both are mitochondrial-relevant peptides but with different mechanisms. SS-31 is a synthetic 4-aa peptide that binds cardiolipin to preserve membrane structure. MOTS-c is an endogenous 16-aa peptide encoded by mitochondrial DNA that activates AMPK and modulates nuclear gene expression. They target different aspects of mitochondrial biology.
▶ What is the half-life of SS-31?
Approximately 3 hours plasma in humans, sufficient for once-daily subcutaneous dosing in the Stealth clinical program.
CITED LITERATURE
- Szeto HH, Schiller PW. Mitochondria-targeted peptide accelerates ATP recovery and reduces ischemic kidney injury. J Am Soc Nephrol 2011. link
- Pfeiffer K, Gohil V, Stuart RA, et al.. Cardiolipin stabilizes respiratory-chain supercomplexes. J Biol Chem 2003. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19